For the third quarter of fiscal 2026 (ended December 31, 2025), Immunovant reported a net loss of $110.6 million, a 43.8% increase from the prior year. Diluted EPS was -$0.61, a 19.7% improvement year-over-year. The company had no revenue. Operating income for the quarter ended September 30, 2019 was -$419,757.
•Net loss of $110.6 million in Q3 FY2026, up 43.8% year-over-year.
•Diluted EPS of -$0.61, improving 19.7% from the prior year.
•No revenue reported for the quarter.
•Operating income of -$419,757 for the quarter ended September 30, 2019.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Immunovant, Inc., a clinical-stage immunology company develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. Founded in 2018, the company is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. Its primary product candidate is IMVT-1402, a human monoclonal antibody that inhibits the neonatal fragment crystallizable receptor (FcRn). This therapy is being investigated for multiple autoimmune conditions, including Graves' disease, rheumatoid arthritis, Sjögren's disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company operates as a subsidiary of Roivant Sciences Ltd. and is headquartered in Durham, North Carolina.
Where is Immunovant (IMVT) listed and in which currency?
Immunovant, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol IMVT. Its shares are traded in U.S. dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, it is subject to the reporting and governance requirements of the U.S. Securities and Exchange Commission.
What sector and industry does Immunovant (IMVT) belong to?
Immunovant operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of novel therapies, particularly monoclonal antibodies for autoimmune diseases. The biotechnology industry is characterized by high research intensity, long development timelines, and significant regulatory oversight. Immunovant's work in immunology places it at the intersection of drug discovery and clinical development for chronic autoimmune conditions.
Where is Immunovant (IMVT) headquartered and what markets does it serve?
Immunovant, Inc. is headquartered in Durham, North Carolina, United States. The company primarily serves the U.S. market, as indicated by its listing on a U.S. exchange and its focus on developing therapies for autoimmune diseases prevalent in the region. While its clinical trials may involve international sites, its operations and regulatory filings are centered in the United States. As a subsidiary of Roivant Sciences Ltd., it also benefits from a broader network within the biopharmaceutical ecosystem.